Sajjad Raza1, Joseph F Sabik2, Ponnuthurai Ainkaran3, Eugene H Blackstone4. 1. Department of Thoracic and Cardiovascular Surgery, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio. 2. Department of Thoracic and Cardiovascular Surgery, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio. Electronic address: sabikj@ccf.org. 3. Department of Quantitative Health Sciences, Research Institute, Cleveland Clinic, Cleveland, Ohio. 4. Department of Thoracic and Cardiovascular Surgery, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio; Department of Quantitative Health Sciences, Research Institute, Cleveland Clinic, Cleveland, Ohio.
Abstract
OBJECTIVES: To determine 4-decade temporal trends in the prevalence of diabetes and cardiovascular risk factors among patients undergoing coronary artery bypass grafting (CABG) and to compare in-hospital outcomes, resource utilization, and long-term survival after CABG in diabetics versus nondiabetics. METHODS: From January 1972 to January 2011, 10,362 pharmacologically treated diabetics and 45,139 nondiabetics underwent first-time CABG. Median follow-up was 12 years. Direct technical cost data were available from 2003 onward (n = 4679). Propensity matching by diabetes status was used for outcome comparisons. Endpoints were in-hospital adverse events, resource utilization, and long-term survival. RESULTS: Diabetics undergoing CABG increased from 7% in the 1970s to 37% in the 2000s. Their outcomes were worse, with more (P < .05) in-hospital deaths (2.0% vs 1.3%), deep sternal wound infections (2.3% vs 1.2%), strokes (2.2% vs 1.4%), renal failure (4.0% vs 1.3%), and prolonged postoperative hospital stay (9.6% vs 6.0%); and their hospital costs were 9% greater (95% confidence interval 7%-11%). Survival after CABG among diabetics versus nondiabetics at 1, 5, 10, and 20 years was also worse: 94% versus 94%, 80% versus 84%, 56% versus 66%, and 20% versus 32%, respectively. Propensity-matched patients incurred similar costs, but the prevalence of postoperative deep sternal wound infections and stroke, as well as long-term survival, remained worse in diabetics. CONCLUSIONS: Diabetes is both a marker for high-risk, resource-intensive, and expensive care after CABG and an independent risk factor for reduced long-term survival. These issues, coupled with the increasing proportion of patients needing CABG who have diabetes, are a growing challenge in reining in health care costs.
OBJECTIVES: To determine 4-decade temporal trends in the prevalence of diabetes and cardiovascular risk factors among patients undergoing coronary artery bypass grafting (CABG) and to compare in-hospital outcomes, resource utilization, and long-term survival after CABG in diabetics versus nondiabetics. METHODS: From January 1972 to January 2011, 10,362 pharmacologically treated diabetics and 45,139 nondiabetics underwent first-time CABG. Median follow-up was 12 years. Direct technical cost data were available from 2003 onward (n = 4679). Propensity matching by diabetes status was used for outcome comparisons. Endpoints were in-hospital adverse events, resource utilization, and long-term survival. RESULTS:Diabetics undergoing CABG increased from 7% in the 1970s to 37% in the 2000s. Their outcomes were worse, with more (P < .05) in-hospital deaths (2.0% vs 1.3%), deep sternal wound infections (2.3% vs 1.2%), strokes (2.2% vs 1.4%), renal failure (4.0% vs 1.3%), and prolonged postoperative hospital stay (9.6% vs 6.0%); and their hospital costs were 9% greater (95% confidence interval 7%-11%). Survival after CABG among diabetics versus nondiabetics at 1, 5, 10, and 20 years was also worse: 94% versus 94%, 80% versus 84%, 56% versus 66%, and 20% versus 32%, respectively. Propensity-matched patients incurred similar costs, but the prevalence of postoperative deep sternal wound infections and stroke, as well as long-term survival, remained worse in diabetics. CONCLUSIONS:Diabetes is both a marker for high-risk, resource-intensive, and expensive care after CABG and an independent risk factor for reduced long-term survival. These issues, coupled with the increasing proportion of patients needing CABG who have diabetes, are a growing challenge in reining in health care costs.
Authors: William H Herman; Thomas J Hoerger; Michael Brandle; Katherine Hicks; Stephen Sorensen; Ping Zhang; Richard F Hamman; Ronald T Ackermann; Michael M Engelgau; Robert E Ratner Journal: Ann Intern Med Date: 2005-03-01 Impact factor: 25.391
Authors: V H Thourani; W S Weintraub; B Stein; S S Gebhart; J M Craver; E L Jones; R A Guyton Journal: Ann Thorac Surg Date: 1999-04 Impact factor: 4.330
Authors: Gregory Pattakos; Colleen G Koch; Mariano E Brizzio; Lillian H Batizy; Joseph F Sabik; Eugene H Blackstone; Michael S Lauer Journal: Arch Intern Med Date: 2012-08-13
Authors: Masashi Kawamura; Michael J Paulsen; Andrew B Goldstone; Yasuhiro Shudo; Hanjay Wang; Amanda N Steele; Lyndsay M Stapleton; Bryan B Edwards; Anahita Eskandari; Vi N Truong; Kevin J Jaatinen; Arnar B Ingason; Shigeru Miyagawa; Yoshiki Sawa; Y Joseph Woo Journal: Cardiovasc Diabetol Date: 2017-11-02 Impact factor: 9.951
Authors: Jef Van den Eynde; Abel Van Vlasselaer; Annoushka Laenen; Delphine Szecel; Bart Meuris; Tom Verbelen; Steven Jacobs; Peter Verbrugghe; Wouter Oosterlinck Journal: J Cardiothorac Surg Date: 2021-07-20 Impact factor: 1.637